

January 18, 2008

Company Name	Oak Capital Corporation
Name of Representative	Hiroyasu Takei, Representative Director and Chairman
Securities Code Number	3113
Market of Public Listing	2 nd Sections of TSE, OSE and NSE
Contact Person	Koji Kirimura, Manager Public & Investor Relations Dept. (irinfo2@oakcapital.jp)

Portfolio company Biosensors securing CE Mark approval for flagship product

Oak Capital's portfolio company Biosensors International Group, Ltd. ("Biosensors") today announced that it has been officially granted the long-awaited CE Mark approval for its in-house developed drug-eluting stent (DES) BioMatrix®.

This CE Mark approval will allow Biosensors to launch sales of the BioMatrix DES commencing April 1, 2008. In view of the catheter market's demand for advanced equipment and the likelihood that Biosensor's superior technology and products will capture a sizable market share, Oak Capital has judged that Biosensors' performance will receive a significant boost from sales of the lucrative DES product*.

In its News Release of today, Biosensors has mentioned that Terumo Corporation ("Terumo"), a licensee of Biosensors' BioMatrix technology, also received CE Mark approval for its NOBORI™ DES system. Based on the licensing agreement with Terumo, royalty income from Terumo's future sales of the NOBORI DES are also expected to contribute to Biosensors' bottom line.

The CE (Conformité Européenne) Mark is a mandatory marking for medical devices and other product groups to indicate conformity with the essential health and safety requirements stipulated in the European Directives. CE marking is a prerequisite to marketing products in the European Economic Area as well as several non-EEA countries accepting the CE Mark.

The BioMatrix DES system uses a biodegradable polymer coating which breaks down into biocompatible compounds coincident with the controlled release of Biosensors' proprietary anti-inflammatory drug Biolimus A9. The BioMatrix DES, together with the NOBORI DES, is poised to become the only drug-eluting stent on the market incorporating a biodegradable polymer.

** Note: The DES market is worth US\$ 5 billion (approx. 500 billion yen) a year (Science Daily News, 12 January, 2008)*

For further details, please consult the following News Release by Biosensors:

http://www.listedcompany.com/ir/biosensors/newsroom/Press_Release_BioMatrix_CE_Mark_Approval.pdf

[Reference]

Outline of Biosensors

Company name:	BIOSENSORS INTERNATIONAL GROUP, LTD.
Website:	http://www.biosensorsintl.com
Head office:	Cedar House, 41 Cedar Avenue, Hamilton HM 12, Bermuda (holding company)
Establishment:	March 1998
Capital stock:	US\$ 91 million
Major holders:	DB Nominees (S) Pte Ltd, HSBC (Singapore) Nominees Pte Ltd, The Linstar Alaska Trust, Oak Capital Corporation, others (as of September 30, 2007, Oak Capital held 48,900,000 shares in the Company)
Representative:	Yoh-Chie Lu, Chairman and CEO
Business description:	Development, manufacturing and marketing of high-tech medical devices used in interventional cardiology and critical-care procedures.